Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep 16;31(30):3782–3790. doi: 10.1200/JCO.2012.47.4007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — Survival and cumulative incidence (CI) of disease progression stratified by donor KIR2DL1 allelic groups and the presence of HLA-C receptor-ligand mismatch. Shown are the (A) overall survival probability and (B) CI of disease progression or relapse among different groups of patients with hematologic malignancy. Group 1, patients with a KIR2DL1-R²⁴⁵ homozygous (RR) or KIR2DL1-R²⁴⁵/C²⁴⁵ heterozygous (RC) donor and HLA-C receptor-ligand mismatch; group 2, patients with a KIR2DL1 RR or RC donor but not HLA-C receptor-ligand mismatched; group 3, patients who received a KIR2DL1-C²⁴⁵ homozygous (CC) graft with or without HLA-C receptor-ligand mismatch. P_{group 1/group 3}, P value between group 1 and group 3; P_{group 2/group 3}, P value between group 2 and group 3.